27 completed, 2 unknown, 2 withdrawn, 1 approved for marketing. 21 Phase 3, 10 Phase 2, 3 Phase 1, 3 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 20, Unknown 1 |
| Phase 2 | 10 | Completed 10 |
| Phase 1 | 3 | Completed 3 |
| Phase 4 | 3 | Withdrawn 2, Recruiting 1 |
| Not applicable | 1 | Terminated 1 |
Follow pibrentasvir: new trials by email Literature Review of pibrentasvir trials Research Report on pibrentasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glecaprevir/Pibrentasvir for the Treatment of PTSD Glecaprevir / Pibrentasvir Pill - PTSD | Phase 2 / Phase 3 | Completed | White River Junction Veterans Affairs Medical Center | 10 | 2023-04-01 | 2024-08-29 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) Glecaprevir/Pibrentasvir (GLE/PIB) - Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 286 | 2021-08-24 | 2025-04-06 |
| Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor glecaprevir/pibrentasvir (GLE/PIB) - Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of | Phase 1 / Phase 2 | Completed | University of California, San Diego | 12 | 2021-05-28 | 2022-05-24 |
| Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet, Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet - Hepatitis C, Liver Inflammation | Not applicable | Terminated | Kirby Institute | 21 | 2021-02-12 | 2026-05-26 |
| Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] - End Stage Renal Disease, Chronic Hepatitis c | Phase 4 | Withdrawn | Massachusetts General Hospital | 2020-11-13 | 2022-03-08 | |
| Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir Sofosbuvir 400mg [Sovaldi], Glecaprevir/pibrentasvir (300mg/120mg) - Hepatitis C | Phase 4 | Recruiting | Kirby Institute | 30 | 2020-02-11 | 2026-07-29 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C Direct-acting antiviral agents - Hepatitis C, Chronic | Unknown | Qing XIe | 300 | 2019-03-06 | 2021-07-07 | |
| Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant glecaprevir/pibrentasvir tablets - Kidney Failure, Kidney Diseases | Phase 4 | Withdrawn | Raymond T. Chung, MD | 2019-02-15 | 2019-06-03 | |
| Transplantation Using Hepatitis C Positive Donors, A Safety Trial Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion - Lung Transplant Infection, Heart Transplant Infection | Phase 3 | Unknown | Jordan Feld | 40 | 2018-08-06 | 2019-07-12 |
| A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 100 | 2018-06-06 | 2020-03-17 |
| A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret Mavyret - Hepatitis C | Phase 2 | Completed | NYU Langone Health | 20 | 2018-05-12 | 2021-09-05 |
| Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients glecaprevir (300mg)/pibrentasvir (120mg) - Hepatitis C, Chronic | Phase 3 | Completed | Kirby Institute | 380 | 2017-08-21 | 2019-12-11 |
| A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 343 | 2017-04-28 | 2020-07-13 |
| Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet - Hepatitis C, HCV | Phase 3 | Completed | University of Florida | 177 | 2017-04-20 | 2020-02-26 |
| A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) ABT-493 coformulated with ABT-530 - Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection | Phase 3 | Completed | AbbVie | 153 | 2016-05-17 | 2021-07-13 |
| A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) glecaprevir/pibrentasvir - Chronic Hepatitis C, HCV | Phase 3 | Completed | AbbVie | 100 | 2016-04-22 | 2021-07-13 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection ABT-493/ABT-530, sofosbuvir (SOF), ribavirin (RBV) - Chronic Hepatitis C Virus, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 136 | 2016-04-08 | 2021-07-16 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection ABT-493/ABT-530, OBV/PTV/r - Chronic Hepatitis C Virus, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 295 | 2016-02-22 | 2021-07-16 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis ABT-493/ABT-530 - Hepatitis C Virus Infection, Chronic Hepatitis C | Phase 3 | Completed | AbbVie | 146 | 2015-12-07 | 2021-07-13 |
Showing 20 of 34. Sign in to see all of them.
Hepatitis C (31) · Hepatitis C, Chronic (21) · Fibrosis (3) · Infections (3) · Renal Insufficiency (3) · Acquired Immunodeficiency Syndrome (1) · Hepatitis (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Stress Disorders, Post-Traumatic (1)
AbbVie (22) · Kirby Institute (3) · Jordan Feld (1) · Massachusetts General Hospital (1) · NYU Langone Health (1) · Ohio State University (1) · Qing XIe (1) · Raymond T. Chung, MD (1) · University of California, San Diego (1) · University of Florida (1) · White River Junction Veterans Affairs Medical Center (1)
United States (13) · Australia (5) · Canada (5) · New Zealand (4) · France (3) · Germany (3) · United Kingdom (3) · Italy (2) · Puerto Rico (2) · Spain (2) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · China (1)
Armen Asatryan, MD (2) · David Pugatch, MD (2) · Bradley V Watts, MD, MPH (1) · David R Nelson, MD (1) · Gregory Dore (1) · Jordan Feld, MD, MPH (1) · Luis Angel, MD (1) · Marianne Martinello, MD, PhD (1) · Qing Xie, MD (1) · Raymond T Chung, MD (1) · Reem Daloul, MD (1)
PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 30529905, PMID 30868245, PMID 29180522, PMID 35174470, PMID 26711747, PMID 26778412, PMID 27456384, PMID 28128852, PMID 28412293, PMID 28865152, PMID 28941361, PMID 28951228, PMID 29020583, PMID 29263061, PMID 31401140, PMID 31655134, PMID 31682879, PMID 32389183, PMID 32949786, PMID 34023351, PMID 35220658, PMID 41297677, PMID 42340583
2015 (10), 2014 (2), 2016 (1)